
Aleš Kvasnička
- Spesialingeniør; PhD
- +47 230 70 911
Education
- 2020-2024: PhD in Medical chemistry and Clinical Biochemistry, Palacký University Olomouc, Czechia
- 2018-2020: MSc in Biochemistry, Palacký University Olomouc, Czechia
- 2015-2018: BSc in Biochemistry, Palacký University Olomouc, Czechia
Affiliation
- Metabolomics & Metabolic Molecular Biology Group, Department of Medical Biochemistry, Oslo University Hospital - Rikshospitalet, Norway
Research Summary
Dr. Kvasnička is specialized in clinical lipidomics methods and applications. He optimized targeted lipidomics methods for lipid profiling and/or specific diagnostic lipid panels. His area of research revolves around deciphering the pathobiochemical mechanism of various diseases (including rheumatological, cardiovascular, neurodegenerative diseases, cancer and others) and leveraging these insights into clinical translation.
Highlights:
- Lipidomics evaluation of the impact on the lipid metabolism of hyperuricemia and gout patients and the response to treatment. Kvasnička et al. (2023)
- Discovery of systematic trend in polyunsaturated phosphatidylcholines in patients surviving heart failure. Kvasnička et al. (2024)
- Review article on clinical lipidomics applications and development. Kvasnička et al. (2023)
- Member of the Editorial Advisory Board of the Metabolomics journal (ISSN 1573-3890)
- Member of the Early Career Members Network Committee of the Metabolomics Society (2024-2025)
- Chair of the Young Scientists Committee of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) (2024-2025)
- Reviewer for journals: Metabolomics, Lipids in Health and Disease, Communications Biology, Communications Medicine, Inflammation, Journal of Proteome Research, and others
Work Experience
- 2024 October-Present: Spesialingeniør at the Department of Medical Biochemistry, Oslo University Hospital, Norway
- 2020 September-2024 September: Assistant and junior researcher at the Faculty of Medicine and Dentistry, Palacký University Olomouc, Czechia
- 2023 January-2024 September: Researcher at the Laboratory of Inherited Metabolic disorders, University Hospital Olomouc, Czechia
- 2024 March-2024 April: Guest researcher at the Lipid Metabolism: Analysis and Integration (LMAI) – (Maria Fedorova's lab), Technische Universität Dresden, Germany
- 2023 May-2023 June: Guest Researcher at the Section of Neuropathology Research (Jens Pahnke's lab), Oslo University Hospital, Rikshospitalet, Norway
- 2022 July-2022 August: Guest Researcher at the Department of Systems Biology (Hiroshi Tsugawa's lab), Tokyo University of Agriculture and Technology, Japan
- 2019 September-2020 February: Guest Researcher at the Institute of Pharmaceutical Sciences (Michael Lämmerhofer's lab), Eberhard Karls Universität Tübingen, Germany
Links
NB: Visit our NEWS PAGE for the latest updates and our Gallery for group social events!
Publications 2025
MInfer: Bridging MetaboAnalyst and Jacobian analysis for metabolomic networks
Comput Methods Programs Biomed, 263, 108672
DOI 10.1016/j.cmpb.2025.108672, PubMed 39999596
Publications 2024
Wide metabolite coverage LC-MS/MS assay for the diagnosis of inherited metabolic disorders in urine
Talanta, 271, 125699
DOI 10.1016/j.talanta.2024.125699, PubMed 38262132
Patients with Neurodegenerative Proteinopathies Exhibit Altered Tryptophan Metabolism in the Serum and Cerebrospinal Fluid
ACS Chem Neurosci, 15 (3), 582-592
DOI 10.1021/acschemneuro.3c00611, PubMed 38194490
Long-chain polyunsaturated fatty acid-containing phosphatidylcholines predict survival rate in patients after heart failure
Heliyon, 10 (21), e39979
DOI 10.1016/j.heliyon.2024.e39979, PubMed 39553601
Changes in lipid metabolism track with the progression of neurofibrillary pathology in tauopathies
J Neuroinflammation, 21 (1), 78
DOI 10.1186/s12974-024-03060-4, PubMed 38539208
Parallel Metabolomics and Lipidomics of a PSMA/GCPII Deficient Mouse Model Reveal Alteration of NAAG Levels and Brain Lipid Composition
ACS Chem Neurosci, 15 (7), 1342-1355
DOI 10.1021/acschemneuro.3c00494, PubMed 38377674
MS-DIAL 5 multimodal mass spectrometry data mining unveils lipidome complexities
Nat Commun, 15 (1), 9903
DOI 10.1038/s41467-024-54137-w, PubMed 39609386
Sex-dependent efficacy of sphingosine-1-phosphate receptor agonist FTY720 in mitigating Huntington's disease
Pharmacol Res, 211, 107557
DOI 10.1016/j.phrs.2024.107557, PubMed 39725338
Publications 2023
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
Arthritis Res Ther, 25 (1), 234
DOI 10.1186/s13075-023-03204-6, PubMed 38042879
Clinical lipidomics in the era of the big data
Clin Chem Lab Med, 61 (4), 587-598
DOI 10.1515/cclm-2022-1105, PubMed 36592414
Rapid and efficient LC-MS/MS diagnosis of inherited metabolic disorders: a semi-automated workflow for analysis of organic acids, acylglycines, and acylcarnitines in urine
Clin Chem Lab Med, 61 (11), 2017-2027
DOI 10.1515/cclm-2023-0084, PubMed 37207286
Publications 2022
Altered Plasma, Urine, and Tissue Profiles of Sulfatides and Sphingomyelins in Patients with Renal Cell Carcinoma
Cancers (Basel), 14 (19)
DOI 10.3390/cancers14194622, PubMed 36230546
Publications 2021
Lipidomic and metabolomic analysis reveals changes in biochemical pathways for non-small cell lung cancer tissues
Biochim Biophys Acta Mol Cell Biol Lipids, 1867 (2), 159082
DOI 10.1016/j.bbalip.2021.159082, PubMed 34793969
SLIDE-Novel Approach to Apocrine Sweat Sampling for Lipid Profiling in Healthy Individuals
Int J Mol Sci, 22 (15)
DOI 10.3390/ijms22158054, PubMed 34360820
Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients
Diagnostics (Basel), 11 (11)
DOI 10.3390/diagnostics11112027, PubMed 34829374